Moreover, a clinical trial for triple-negative breast cancer is currently proceeding to test the checkpoint inhibitor PDR001 in combination with Canakinumab, an anti-IL-1β antibody (147). The gene discussed is IL1B; the disease is triple-negative breast carcinoma.